ArticleJournal of inorganic biochemistry2012
Platinum(IV)-chlorotoxin (CTX) conjugates for targeting cancer cells.
Article in Journal of inorganic biochemistry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 100 citations in OpenAlex.
- Gold- and Platinum-Peptide Bioconjugates in Cancer Therapy: Recent Advances and Future Directions.Pharmaceutics · 2026Review
- Venom-derived peptides for breaking through the glass ceiling of drug development.Frontiers in chemistry · 2024Review
- Chlorotoxin and Lung Cancer: A Targeting Perspective for Drug Delivery.Pharmaceutics · 2022Article
- A Conjugate between Lqh-8/6, a Natural Peptide Analogue of Chlorotoxin, and Doxorubicin Efficiently Induces Glioma Cell Death.Biomedicines · 2022Article
- A Cytochrome c-Chlorotoxin Hybrid Protein as a Possible Antiglioma Drug.ChemMedChem · 2020Article
- Review
- Chlorotoxin targets ERα/VASP signaling pathway to combat breast cancer.Cancer medicine · 2019Article
- Targeted Delivery to Tumors: Multidirectional Strategies to Improve Treatment Efficiency.Cancers · 2019Review
- Targeting Glioblastoma Cells Expressing CD44 with Liposomes Encapsulating Doxorubicin and Displaying Chlorotoxin-IgG Fc Fusion Protein.International journal of molecular sciences · 2018Article
- Current Developments in Pt(IV) Prodrugs Conjugated with Bioactive Ligands.Bioinorganic chemistry and applications · 2018Review
- Venom-based peptide therapy: insights into anti-cancer mechanism.Oncotarget · 2017Review
- The Platin-X series: activation, targeting, and delivery.Dalton transactions (Cambridge, England : 2003) · 2016Review
- Integrin-Targeting Knottin Peptide-Drug Conjugates Are Potent Inhibitors of Tumor Cell Proliferation.Angewandte Chemie (International ed. in English) · 2016Article
- The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs.Chemical reviews · 2016Review
- Effects of Animal Venoms and Toxins on Hallmarks of Cancer.Journal of Cancer · 2016Review
- Temozolomide nanoparticles for targeted glioblastoma therapy.ACS applied materials & interfaces · 2015Article
- Chlorotoxin: a helpful natural scorpion peptide to diagnose glioma and fight tumor invasion.Toxins · 2015Review
- Pt(IV) prodrugs designed to bind non-covalently to human serum albumin for drug delivery.Journal of the American Chemical Society · 2014Article
- Synthetic methods for the preparation of platinum anticancer complexes.Chemical reviews · 2014Review
- Targeting mitochondrial DNA with a platinum-based anticancer agent.Chemistry & biology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Cisplatin is one of the most widely used anticancer drugs. Its side effects, however, have motivated researchers to search for equally effective analogs that are better tolerated. Selectively targeting cancer tissue is one promising strategy. For this purpose, a platinum(IV) complex was conjugated to the cancer-targeting peptide chlorotoxin (CTX, TM601) in order to deliver cisplatin selectively to cancer cells. The 1:1 Pt-CTX conjugate was characterized by mass spectrometry and gel electrophoresis. Like most platinum(IV) derivatives, the cytotoxicity of the conjugate was lower in cell culture than that of cisplatin, but greater than those of its Pt(IV) precursor and CTX in several cancer cell lines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.